Not approved, and not yet legal to compound
TB-500 follows the same path as BPC-157: off the FDA's safety list since April 2026 and recommended by an advisory panel in July, but still waiting on FDA action.
TB-500 is often mentioned in the same breath as BPC-157, and its legal status has moved in lockstep with it. Here's where it stands as of October 27, 2026.
The short answer
TB-500 is not FDA-approved for any use, and US compounding pharmacies can't legally make it today. An FDA advisory committee recommended allowing it in compounding in July 2026, but the FDA hasn't finalized that.
What TB-500 is
TB-500 is a synthetic fragment of thymosin beta-4, a protein the body makes naturally. It's promoted online for injury recovery, but human clinical data are limited. That gap was central to the FDA staff's recommendation against approving it for compounding.
Timeline
Late 2023: The FDA placed TB-500 in Category 2, flagging significant safety risks for compounding.
April 2026: The FDA removed TB-500 from Category 2 after its nomination was withdrawn, along with BPC-157 and 10 other peptides. That removal didn't authorize compounding.
July 23, 2026: The FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding TB-500 to the 503A bulks list. FDA staff had proposed that neither form of TB-500, free base or acetate, be included.
October 14, 2026: An interim access policy for compounding certain peptides went to the White House budget office for review. It's not yet known which peptides it covers.
What has to happen before it's legal to compound
The FDA would need to publish a proposed rule adding TB-500 to the bulks list, take public comments, and publish a final rule. Alternatively, the pending interim access policy could allow temporary compounding if it includes TB-500. Neither has happened yet. Our explainer on the July vote walks through the process.
Gray-market TB-500
TB-500 sold online as a "research chemical" isn't legal to market for human use, regardless of disclaimers. The FDA's recent warning letters to peptide sellers have made clear that "research use only" labels don't protect a product that's evidently being sold for people to use. Quality is also uncontrolled: purity, dose, and sterility aren't verified.
Athletes and service members
TB-500 is on the World Anti-Doping Agency's 2026 prohibited list and is banned for US military personnel, with strict liability for positive tests.
What to watch next
Watch for the interim access policy's release and any FDA proposed rule on the July votes. We'll update this page and the FDA status tracker as soon as either appears.
What this article is based on
Checked October 27, 2026. Primary FDA documents are listed first where available.
- FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026
- PharmExec: FDA panel votes to loosen restrictions for four peptides
- GoodRx: Peptide Watch (reviewed October 16, 2026)
- Texas Orthobiologics: The truth about peptides, compounding pharmacies, and FDA regulation
- BSCG: What's changing with peptide regulation in 2026
About this content: The Peptide Verdict is an independent educational publication. Articles are researched and written with AI assistance, edited by our editorial team, and checked against the primary sources listed on each page. They are not reviewed by a medical professional and are not medical, legal, or pharmacy advice. Peptide regulations change quickly; always check the dates shown and confirm current rules. Talk to a licensed clinician before using any peptide or medication.